Literature DB >> 24081456

Development and validation of pedigree classification criteria for frontotemporal lobar degeneration.

Elisabeth M Wood1, Dana Falcone, Eunran Suh, David J Irwin, Alice S Chen-Plotkin, Edward B Lee, Sharon X Xie, Vivianna M Van Deerlin, Murray Grossman.   

Abstract

IMPORTANCE: A significant portion of frontotemporal lobar degeneration (FTLD) is due to inherited gene mutations, and we are unaware of a large sequential series that includes a recently discovered inherited cause of FTLD. There is also great need to develop clinical tools and approaches that will assist clinicians in the identification and counseling of patients with FTLD and their families regarding the likelihood of an identifiable genetic cause.
OBJECTIVES: To ascertain the frequency of inherited FTLD and develop validated pedigree classification criteria for FTLD that provide a standardized means to evaluate pedigree information and insight into the likelihood of mutation-positive genetic test results for C9orf72, MAPT, and GRN.
DESIGN: Information about pedigrees and DNA was collected from 306 serially assessed patients with a clinical diagnosis of FTLD. This information included gene test results for C9orf72, MAPT, and GRN. Pedigree classification criteria were developed based on a literature review of FTLD genetics and pedigree tools and then refined by reviewing mutation-positive and -negative pedigrees to determine differentiating characteristics.
SETTING: Academic medical center. PARTICIPANTS: Patients with FTLD. MAIN OUTCOMES AND MEASURES: Familial risk.
RESULTS: The rate of C9orf72, MAPT, or GRN mutation-positive FTLD in this series was 15.4%. Categories designating the risk level for hereditary cause were termed high, medium, low, apparent sporadic, and unknown significance. Thirty-nine pedigrees (12.7%) met criteria for high, 31 (10.1%) for medium, 46 (15.0%) for low, 91 (29.7%) for apparent sporadic, and 99 (32.4%) for unknown significance. The mutation-detection rates were as follows: high, 64.1%; medium, 29%; low, 10.9%; apparent sporadic, 1.1%; and unknown significance, 7.1%. Mutation-detection rates differed significantly between the high and other categories. CONCLUSIONS AND RELEVANCE: Mutation rates are high in FTLD spectrum disorders, and the proposed criteria provide a validated standard for the classification of FTLD pedigrees. The combination of pedigree criteria and mutation-detection rates has important implications for genetic counseling and testing in clinical settings.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24081456      PMCID: PMC3906581          DOI: 10.1001/jamaneurol.2013.3956

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  39 in total

1.  Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.

Authors:  Mariely DeJesus-Hernandez; Ian R Mackenzie; Bradley F Boeve; Adam L Boxer; Matt Baker; Nicola J Rutherford; Alexandra M Nicholson; NiCole A Finch; Heather Flynn; Jennifer Adamson; Naomi Kouri; Aleksandra Wojtas; Pheth Sengdy; Ging-Yuek R Hsiung; Anna Karydas; William W Seeley; Keith A Josephs; Giovanni Coppola; Daniel H Geschwind; Zbigniew K Wszolek; Howard Feldman; David S Knopman; Ronald C Petersen; Bruce L Miller; Dennis W Dickson; Kevin B Boylan; Neill R Graff-Radford; Rosa Rademakers
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

2.  Classification of primary progressive aphasia and its variants.

Authors:  M L Gorno-Tempini; A E Hillis; S Weintraub; A Kertesz; M Mendez; S F Cappa; J M Ogar; J D Rohrer; S Black; B F Boeve; F Manes; N F Dronkers; R Vandenberghe; K Rascovsky; K Patterson; B L Miller; D S Knopman; J R Hodges; M M Mesulam; M Grossman
Journal:  Neurology       Date:  2011-02-16       Impact factor: 9.910

3.  The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration.

Authors:  Chang-En Yu; Thomas D Bird; Lynn M Bekris; Thomas J Montine; James B Leverenz; Ellen Steinbart; Nichole M Galloway; Howard Feldman; Randall Woltjer; Carol A Miller; Elisabeth McCarty Wood; Murray Grossman; Leo McCluskey; Christopher M Clark; Manuela Neumann; Adrian Danek; Douglas R Galasko; Steven E Arnold; Alice Chen-Plotkin; Anna Karydas; Bruce L Miller; John Q Trojanowski; Virginia M-Y Lee; Gerard D Schellenberg; Vivianna M Van Deerlin
Journal:  Arch Neurol       Date:  2010-02

Review 4.  Primary progressive aphasia: clinicopathological correlations.

Authors:  Murray Grossman
Journal:  Nat Rev Neurol       Date:  2010-02       Impact factor: 42.937

5.  Genetic contribution of FUS to frontotemporal lobar degeneration.

Authors:  T Van Langenhove; J van der Zee; K Sleegers; S Engelborghs; R Vandenberghe; I Gijselinck; M Van den Broeck; M Mattheijssens; K Peeters; P P De Deyn; M Cruts; C Van Broeckhoven
Journal:  Neurology       Date:  2010-02-02       Impact factor: 9.910

6.  TARDBP variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea.

Authors:  Gabor G Kovacs; Jill R Murrell; Sandor Horvath; Laszlo Haraszti; Katalin Majtenyi; Maria J Molnar; Herbert Budka; Bernardino Ghetti; Salvatore Spina
Journal:  Mov Disord       Date:  2009-09-15       Impact factor: 10.338

7.  Mutation within TARDBP leads to frontotemporal dementia without motor neuron disease.

Authors:  B Borroni; C Bonvicini; A Alberici; E Buratti; C Agosti; S Archetti; A Papetti; C Stuani; M Di Luca; M Gennarelli; A Padovani
Journal:  Hum Mutat       Date:  2009-11       Impact factor: 4.878

8.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.

Authors:  Katya Rascovsky; John R Hodges; David Knopman; Mario F Mendez; Joel H Kramer; John Neuhaus; John C van Swieten; Harro Seelaar; Elise G P Dopper; Chiadi U Onyike; Argye E Hillis; Keith A Josephs; Bradley F Boeve; Andrew Kertesz; William W Seeley; Katherine P Rankin; Julene K Johnson; Maria-Luisa Gorno-Tempini; Howard Rosen; Caroline E Prioleau-Latham; Albert Lee; Christopher M Kipps; Patricia Lillo; Olivier Piguet; Jonathan D Rohrer; Martin N Rossor; Jason D Warren; Nick C Fox; Douglas Galasko; David P Salmon; Sandra E Black; Marsel Mesulam; Sandra Weintraub; Brad C Dickerson; Janine Diehl-Schmid; Florence Pasquier; Vincent Deramecourt; Florence Lebert; Yolande Pijnenburg; Tiffany W Chow; Facundo Manes; Jordan Grafman; Stefano F Cappa; Morris Freedman; Murray Grossman; Bruce L Miller
Journal:  Brain       Date:  2011-08-02       Impact factor: 13.501

9.  A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.

Authors:  Alan E Renton; Elisa Majounie; Adrian Waite; Javier Simón-Sánchez; Sara Rollinson; J Raphael Gibbs; Jennifer C Schymick; Hannu Laaksovirta; John C van Swieten; Liisa Myllykangas; Hannu Kalimo; Anders Paetau; Yevgeniya Abramzon; Anne M Remes; Alice Kaganovich; Sonja W Scholz; Jamie Duckworth; Jinhui Ding; Daniel W Harmer; Dena G Hernandez; Janel O Johnson; Kin Mok; Mina Ryten; Danyah Trabzuni; Rita J Guerreiro; Richard W Orrell; James Neal; Alex Murray; Justin Pearson; Iris E Jansen; David Sondervan; Harro Seelaar; Derek Blake; Kate Young; Nicola Halliwell; Janis Bennion Callister; Greg Toulson; Anna Richardson; Alex Gerhard; Julie Snowden; David Mann; David Neary; Michael A Nalls; Terhi Peuralinna; Lilja Jansson; Veli-Matti Isoviita; Anna-Lotta Kaivorinne; Maarit Hölttä-Vuori; Elina Ikonen; Raimo Sulkava; Michael Benatar; Joanne Wuu; Adriano Chiò; Gabriella Restagno; Giuseppe Borghero; Mario Sabatelli; David Heckerman; Ekaterina Rogaeva; Lorne Zinman; Jeffrey D Rothstein; Michael Sendtner; Carsten Drepper; Evan E Eichler; Can Alkan; Ziedulla Abdullaev; Svetlana D Pack; Amalia Dutra; Evgenia Pak; John Hardy; Andrew Singleton; Nigel M Williams; Peter Heutink; Stuart Pickering-Brown; Huw R Morris; Pentti J Tienari; Bryan J Traynor
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

10.  Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features.

Authors:  Colin J Mahoney; Jon Beck; Jonathan D Rohrer; Tammaryn Lashley; Kin Mok; Tim Shakespeare; Tom Yeatman; Elizabeth K Warrington; Jonathan M Schott; Nick C Fox; Martin N Rossor; John Hardy; John Collinge; Tamas Revesz; Simon Mead; Jason D Warren
Journal:  Brain       Date:  2012-03       Impact factor: 13.501

View more
  57 in total

1.  Heritability in frontotemporal dementia: more missing pieces?

Authors:  Kieren Po; Felicity V C Leslie; Natalie Gracia; Lauren Bartley; John B J Kwok; Glenda M Halliday; John R Hodges; James R Burrell
Journal:  J Neurol       Date:  2014-08-26       Impact factor: 4.849

2.  Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration.

Authors:  David J Irwin; Alberto Lleó; Sharon X Xie; Corey T McMillan; David A Wolk; Edward B Lee; Viviana M Van Deerlin; Leslie M Shaw; John Q Trojanowski; Murray Grossman
Journal:  Ann Neurol       Date:  2017-08-19       Impact factor: 10.422

3.  Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration.

Authors:  Corey T McMillan; Jon B Toledo; Brian B Avants; Philip A Cook; Elisabeth M Wood; Eunran Suh; David J Irwin; John Powers; Christopher Olm; Lauren Elman; Leo McCluskey; Gerard D Schellenberg; Virginia M-Y Lee; John Q Trojanowski; Vivianna M Van Deerlin; Murray Grossman
Journal:  Neurobiol Aging       Date:  2013-12-02       Impact factor: 4.673

Review 4.  Primary Progressive Aphasia and Stroke Aphasia.

Authors:  Murray Grossman; David J Irwin
Journal:  Continuum (Minneap Minn)       Date:  2018-06

5.  Linguistic Aspects of Primary Progressive Aphasia.

Authors:  Murray Grossman
Journal:  Annu Rev Linguist       Date:  2017-10-20

6.  Biomarkers in the primary progressive aphasias.

Authors:  Murray Grossman
Journal:  Aphasiology       Date:  2014-09       Impact factor: 2.773

7.  Divergent patterns of TDP-43 and tau pathologies in primary progressive aphasia.

Authors:  Lucia A A Giannini; Sharon X Xie; Corey T McMillan; Mendy Liang; Andrew Williams; Charles Jester; Katya Rascovsky; David A Wolk; Sharon Ash; Edward B Lee; John Q Trojanowski; Murray Grossman; David J Irwin
Journal:  Ann Neurol       Date:  2019-03-28       Impact factor: 10.422

8.  Perfusion alterations converge with patterns of pathological spread in transactive response DNA-binding protein 43 proteinopathies.

Authors:  Pilar M Ferraro; Charles Jester; Christopher A Olm; Katerina Placek; Federica Agosta; Lauren Elman; Leo McCluskey; David J Irwin; John A Detre; Massimo Filippi; Murray Grossman; Corey T McMillan
Journal:  Neurobiol Aging       Date:  2018-04-17       Impact factor: 4.673

9.  A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes.

Authors:  Alberto Lleó; David J Irwin; Ignacio Illán-Gala; Corey T McMillan; David A Wolk; Edward B Lee; Vivianna M Van Deerlin; Leslie M Shaw; John Q Trojanowski; Murray Grossman
Journal:  JAMA Neurol       Date:  2018-06-01       Impact factor: 18.302

10.  Myelin oligodendrocyte basic protein and prognosis in behavioral-variant frontotemporal dementia.

Authors:  David J Irwin; Corey T McMillan; EunRan Suh; John Powers; Katya Rascovsky; Elisabeth M Wood; Jon B Toledo; Steven E Arnold; Virginia M-Y Lee; Vivianna M Van Deerlin; John Q Trojanowski; Murray Grossman
Journal:  Neurology       Date:  2014-07-03       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.